Search
01/06/2022
Ocular involvement in patients with primary central-nervous-system lymphoma: Analysis of a multicentre study in Spain
Mercadal, S, Alana, M, Barcelo, MI, Bruixola, G, Lopez-Pereira, P, Bobillo, S, Dlouhy, I, Agud, RC, Molina, EG, Martinez, P, Cacabelos, P, Muntanola, A, Garcia-Catalan, G, Sancho, JM, Campos, I, Lado, T, Salar, A, Caballero, AC, Sole-Rodriguez, M, Velasco, R. Ocular involvement in patients with primary central-nervous-system lymphoma: Analysis of a multicentre study in Spain. BRITISH JOURNAL OF HAEMATOLOGY. 2022; 197(6)DOI:10.1111/bjh.18148. PMID:35307813. IF:6.500(Q1/3D).
01/06/2022
Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT (vol 57, pg 416, 2022)
Hernandez-Boluda, JC, Pereira, A, Zinger, N, Gras, L, Martino, R, Nikolousis, E, Finke, J, Chinea, A, Rambaldi, A, Robin, M, Saccardi, R, Natale, A, Snowden, JA, Tsirigotis, P, Vallejo, C, Wulf, G, Xicoy, B, Russo, D, Maertens, J, Daguindau, E, Lenhoff, S, Hayden, P, Czerw, T, McLornan, DP, Yakoub-Agha, I. Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT (vol 57, pg 416, 2022). BONE MARROW TRANSPLANTATION. 2022; 57(6)DOI:10.1038/s41409-022-01652-3. PMID:35361897. IF:4.800(Q1/2D).
01/06/2022
Prognostic value of a new clinically-based classification system in patients with CMML undergoing allogeneic HCT: a retrospective analysis of the EBMT-CMWP
Onida, F, Sbianchi, G, Radujkovic, A, Sockel, K, Kroger, N, Sierra, J, Socie, G, Cornelissen, J, Poire, X, Raida, L, Bourhis, JH, Finke, J, Passweg, J, Salmenniemi, U, Schouten, HC, Beguin, Y, Martin, S, Deconinck, E, Ganser, A, Zver, S, Lioure, B, Rohini, R, Koster, L, Hayden, P, Iacobelli, S, Robin, M, Yakoub-Agha, I. Prognostic value of a new clinically-based classification system in patients with CMML undergoing allogeneic HCT: a retrospective analysis of the EBMT-CMWP. BONE MARROW TRANSPLANTATION. 2022; 57(6)DOI:10.1038/s41409-021-01555-9. PMID:35352038. IF:4.800(Q1/2D).
01/06/2022
The EHA Research Roadmap: Malignant Lymphoid Diseases
Dreyling, M, Andre, M, Gokbuget, N, Tilly, H, Jerkeman, M, Gribben, J, Ferreri, A, Morel, P, Stilgenbauer, S, Fox, C, Ribera, JM, Zweegman, S, Aurer, I, Bodor, C, Burkhardt, B, Buske, C, Caballero, MD, Campo, E, Chapuy, B, Davies, A, de Leval, L, Doorduijn, J, Federico, M, Gaulard, P, Gay, F, Ghia, P, Gronbaek, K, Goldschmidt, H, Kersten, MJ, Kiesewetter, B, Landman-Parker, J, Le Gouill, S, Lenz, G, Leppa, S, Lopez-Guillermo, A, Macintyre, E, Mantega, MVM, Moreau, P, Moreno, C, Nadel, B, Okosun, J, Owen, R, Pospisilova, S, Pott, C, Robak, T, Spina, M, Stamatopoulos, K, Stary, J, Tarte, K, Tedeschi, A, Thieblemont, C, Trappe, RU, Trumper, LH, Salles, G. The EHA Research Roadmap: Malignant Lymphoid Diseases. Hemasphere. 2022; 6(6)DOI:10.1097/HS9.0000000000000726. PMID:35620592. IF:6.600(Q1/3D).